RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer

World News: . []

TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: ) (Tel-Aviv Stock Exchange: ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company’s commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia (RHB-105) in preparation for potential U.S. commercial launch in the fourth quarter of 2019. In addition, Dr. Almenoff will oversee the clinical development of RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections and the pivotal Phase 3 study planned to be initiated in the second half of 2019.

With over 20 years of experience in the pharmaceutical industry, Dr. Almenoff served in various roles, including the President and Chief Medical Officer of Furiex Pharmaceuticals (acquired by Actavis plc, now Allergan plc), whose lead product, Viberzi, was approved by the FDA in 2015 for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Prior to joining Furiex, Dr. Almenoff worked at GlaxoSmithKline plc (GSK), where she held various positions of increasing responsibility. She has recently served as a board member and advisor to numerous biopharma companies.

“I am pleased to step into the role of RedHill’s Chief Scientific Officer at this exciting stage, as we are approaching the potential approval of our lead drug candidate, Talicia,” “I look forward to contributing both to the planned launch of Talicia as a potential new standard-of-care therapy for infection and to the development of our promising late-stage clinical pipeline.”

Dr. Almenoff received her B.A. from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Mt. Sinai School of Medicine. She completed post-graduate medical training at Stanford University Medical Center (Internal Medicine and Infectious Diseases) and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians, and has authored more than 50 publications.


Company contact:
Adi Frish
Senior VP Business Development & Licensing
RedHill Biopharma

IR contact (U.S.):
Timothy McCarthy, CFA, MBA
Managing Director, Relationship Manager
LifeSci Advisors, LLC

More news and information about RedHill Biopharma Ltd.

Published By:

Globe Newswire: 12:00 GMT Tuesday 28th May 2019

Published: .

Search for other references to "redhill" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us